Table 1 Baseline characteristics of patients with neuroendocrine liver metastases treated in the HEPAR PLuS trial
From: Automatic healthy liver segmentation for holmium-166 radioembolization dosimetry
N (%) | |
|---|---|
Number of patients | 31 |
Age—median (IQR)a | 65.1 (57.6–70.2) |
Gender | |
Male (%) | 23 (74.2%) |
Female (%) | 8 (25.8%) |
Origin of tumor | |
Pancreas | 10 (32.3%) |
Small intestine | 8 (25.8%) |
Colorectal | 4 (12.9%) |
Lung | 3 (9.7%) |
Unknown primary | 6 (19.4%) |
ECOG | |
0 | 17 (54.8%) |
1 | 13 (41.9%) |
2 | 1 (3.2%) |
WHO grade | |
1 | 12 |
2 | 19 |
Tumorb burden in %—median (IQR) | 6.9% (3.1–22.5%) |
Procedures | 70 |
Pre-treatment | 32 |
Post-treatment | 38 |
Holmium-166 activity in GBq—median (IQR) | 5.4 (3.6–8.0) |
Technetium-99 m activity in MBq—median (IQR) | 52 (50–53) |